AgeX Therapeutics Inc (DELISTED) (AGE:DL)
11.10
-1.50
(-11.90%)
USD |
NYAM |
Mar 26, 16:00
12.18
+1.08
(+9.73%)
After-Hours: 20:00
AgeX Therapeutics Research and Development Expense (Quarterly): 0.218M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 0.218M |
| June 30, 2023 | 0.16M |
| March 31, 2023 | 0.174M |
| December 31, 2022 | 0.208M |
| September 30, 2022 | 0.162M |
| June 30, 2022 | 0.259M |
| March 31, 2022 | 0.396M |
| December 31, 2021 | 0.376M |
| September 30, 2021 | 0.275M |
| June 30, 2021 | 0.481M |
| March 31, 2021 | 0.324M |
| December 31, 2020 | 0.905M |
| Date | Value |
|---|---|
| September 30, 2020 | 0.653M |
| June 30, 2020 | 0.935M |
| March 31, 2020 | 1.221M |
| December 31, 2019 | 1.469M |
| September 30, 2019 | 1.447M |
| June 30, 2019 | 1.65M |
| March 31, 2019 | 1.338M |
| December 31, 2018 | 1.523M |
| September 30, 2018 | 1.332M |
| June 30, 2018 | 1.384M |
| March 31, 2018 | 2.391M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.16M
Minimum
Jun 2023
1.65M
Maximum
Jun 2019
0.6285M
Average
0.386M
Median
Research and Development Expense (Quarterly) Benchmarks
| Homology Medicines Inc (DELISTED) | 1.513M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 0.904M |
| Theriva Biologics Inc | 3.459M |